MolecuLight Featured in Vizient Tech Watch Protection Status
Blog Category: 

By Industry News

MolecuLight's Receipt of Innovative Technology Contract from Vizient Last Year

PITTSBURGH, PA – (December 6, 2022) MolecuLight Corp., a manufacturer in point-of-care fluorescence imaging for the detection of bacteria in wounds, is featured in Vizient's newly released Tech Watch publication as a key technology for visualizing bacterial load and its locations, and helping to reduce surgical site infections. The article Fluorescence Imaging: New technology enables point-of-care surgical wound bacterial assessment is featured in Vizient's Tech Watch (Medical Device) Volume 3 issue, issued this past week.

The Tech Watch article describes how surgical site infections (SSIs) occur in up to 38% of surgeries1 (depending on anatomical location and type of surgery) and account for 20% of all health care acquired infections.2 SSIs are also the costliest of these infections, extending the average length of hospital stays by 9.7 days and costing more than $20,000 per patient admission.3,4

Early and accurate diagnosis of post-surgical bacterial loads and infection is critical to enable prompt treatment before the infection worsens. Some cases require lab testing to accurately diagnose the bacteria colonizing the wound, allowing the offending bacteria to grow and spread and delay effective treatments. Test results can take days to weeks to be available and, if positive, could be too late to prevent infection.

Clinicians need real-time diagnostic tools that they can use at the point-of-care to help provide immediate information on the state of the wound and possible growth of bacterial burden. The article argues that MolecuLight imaging helps eliminate unnecessary subjectivity in assessing wounds for the presence of harmful bacteria by allowing quick and accurate visualization of locations of elevated bacteria load in wounds, along with clinical signs and symptoms. As such, it provides “invaluable real-time information to inform clinical decision making.”

A recent peer reviewed study5 supports this position in demonstrating the benefits of using MolecuLight to help clinician visualize bacterial burden in surgical site wounds.

  • The study reported 76% of surgical sites that reach the stage of referral to a wound specialist had clinically significant bacterial loads (104 to 109 CFU/g), however only 6.8% exhibited symptoms of infection, resulting in delayed infection management.
  • Point-of-care fluorescence imaging (using the MolecuLight i:X® device) for detecting high bacterial loads has been observed to improve sensitivity by 5.7-fold compared to clinical signs and symptoms alone.
  • Clinician experience with fluorescence imaging and interpretation (>200 imaging sessions) has been found to increase sensitivity of fluorescence imaging to 11.3-fold higher than clinical signs and symptoms alone, and accuracy to 2.6-fold higher.

"Clinicians need an objective means of detecting infection or another surgical wound complication without having to rely on subjective judgment," says Kylie Sandy-Hodgetts, PhD, Founder and inaugural President of the International Surgical Wound Complications Advisory Panel (ISWCAP). "Fluorescence imaging using MolecuLight is positioned to change contemporary paradigms of post-surgical wound management due to its ability to quickly and reliably detect bacterial burden and visualize contamination at the point-of-care."

In addition to the profile in Vizent's Tech Watch, last year the MolecuLight i:X® fluorescence wound imaging device received an Innovative Technology contract from Vizient, Inc., a health care performance improvement company based in the United States. The new Innovative Technology contract for MolecuLight i:X® signifies to Vizient members the device's unique qualities that potentially bring improvement to the health care industry.

"We have been working with MolecuLight since 2021 when Vizient recognized the company as an awarded supplier through our Innovative Technology Program," said Tami Maurer, VP, Contract & Program Services at Vizient, Inc. "Carefully evaluated and selected by our member council of clinical and supply chain professionals, Vizient’s Innovative Technology Program recognizes innovative advancements in care, enabling health care providers to offer the highest quality care while encouraging manufacturers to continue to pioneer new solutions."

The MolecuLight i:X® and DX are imaging devices for the real-time detection of elevated bacterial burden in wounds and are FDA cleared and CE and Health Canada approved. With clinical evidence including over 60 peer-reviewed publications involving 1,500 patients, they are widely used in wound care facilities globally.


  1. Alkaaki A et al. Can J Surg. 2019;62(2):111-117
  2. Klevens RM et al. Public Health Rep. 2007;122(2):160-166
  3. Ban KA et al. J Am Coll Surg. 2017;224(1):59-74
  4. Zimlichman E et al. JAMA Intern Med. 2013;173(22):2039-2046
  5. "Uncovering the high prevalence of bacterial burden in surgical site wounds with point-of-care fluorescence imaging", Sandy Hodgetts, K. et al., Int Wound J. 2021;1–11

About MolecuLight Inc.
MolecuLight is the manufacturer of MolecuLight i:X®, a point-of-care fluorescence imaging device for digital wound measurement and detection of elevated bacterial burden in wounds, with CSS.

The views and opinions expressed in this blog are solely those of the author, and do not represent the views of WoundSource, HMP Global, its affiliates, or subsidiary companies.

Related company: 

Recommended for You

Important Notice: The contents of the website such as text, graphics, images, and other materials contained on the website ("Content") are for informational purposes only. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. The content is not intended to substitute manufacturer instructions. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or product usage. Refer to the Legal Notice for express terms of use.